[HTML][HTML] Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational …
…, ML Steele, A Merkle, B Matthes, C Grah, H Matthes - PloS one, 2018 - journals.plos.org
Background Stage IV non-small cell lung cancer (NSCLC) is associated with a five-year
survival rate of around 1%. Treatment with Viscum album L. (VA) extracts has been shown to …
survival rate of around 1%. Treatment with Viscum album L. (VA) extracts has been shown to …
[HTML][HTML] Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer
A Thronicke, ML Steele, C Grah, B Matthes… - BMC complementary and …, 2017 - Springer
Background Despite improvement of tumour response rates in patients with progressive and
metastatic cancer, immune checkpoint inhibitors (ICM) induce toxicities in cancer patients. …
metastatic cancer, immune checkpoint inhibitors (ICM) induce toxicities in cancer patients. …
[HTML][HTML] KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥ 50%) lung …
…, C Vollbrecht, C Grah, B Matthes… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Pembrolizumab is a standard of care as first line palliative therapy in PD-L1
overexpressing (≥ 50%) non-small cell lung cancer (NSCLC). This study aimed at the …
overexpressing (≥ 50%) non-small cell lung cancer (NSCLC). This study aimed at the …
Network Oncology (NO)-a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine
…, T Breitkreuz, C Paxino, J Gutsch, B Matthes… - Forschende …, 2013 - karger.com
Background: Concepts of integrative oncology (IO), as have been offered by anthroposophic
medicine (AM) for decades, are gaining increasing interest and acceptance. Central …
medicine (AM) for decades, are gaining increasing interest and acceptance. Central …
Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (≥ 50%) NSCLC: Real-world results with special focus on PS≥ 2, brain metastases, and …
…, D Misch, C Vollbrecht, C Grah, B Matthes… - Clinical Lung Cancer, 2021 - Elsevier
Introduction Pembrolizumab is a highly effective standard of care in PD-L1 overexpressing (≥
50%) non–small-cell lung cancer. However, a substantial share of patients from everyday …
50%) non–small-cell lung cancer. However, a substantial share of patients from everyday …
[PDF][PDF] QuaDoSta—a freely configurable system which facilitates multi-centric data collection for healthcare and medical research
…, B Matthes, U Albrecht, H Matthes - MS Medizinische …, 2007 - researchgate.net
The projects EvaMed (Evaluation Anthroposophical Medicine) and the Network Oncology
are two scientific research projects which have been successfully established as nationally …
are two scientific research projects which have been successfully established as nationally …
Total synthesis of the marine sesquiterpene quinone (−)-cyclozonarone
J Schröder, B Matthes, K Seifert - Tetrahedron Letters, 2001 - Elsevier
The total synthesis of the naturally occurring sesquiterpene quinone (−)-cyclozonarone was
achieved starting from (+)-albicanol. Elimination of water led to drima-(8,12),(9,11)-diene, …
achieved starting from (+)-albicanol. Elimination of water led to drima-(8,12),(9,11)-diene, …
Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study
A Thronicke, B Matthes, P von Trott… - Integrative Cancer …, 2020 - journals.sagepub.com
Background: Recent data suggest a beneficial effect of add-on treatment with Viscum album
L (VA) on the survival in cancer patients. The objective of this study was to compare the …
L (VA) on the survival in cancer patients. The objective of this study was to compare the …
[HTML][HTML] Health-Related quality of life in patients with lung cancer applying integrative oncology concepts in a certified cancer centre
…, P von Trott, M Kröz, C Grah, B Matthes… - Evidence-Based …, 2020 - hindawi.com
Background. Pretreatment health-related quality of life (HRQOL) is associated with survival
outcome in lung cancer patients. There is a lack of systematic research on pretreatment …
outcome in lung cancer patients. There is a lack of systematic research on pretreatment …
Biotechnological production and bioactivities of mollisin and two new, structurally related fungal naphthoquinone metabolites
…, A Härtl, HM Dahse, B Matthes… - Chemistry & …, 2005 - Wiley Online Library
The antibiotic and fungicidal deuteromycete Mollisia caesia S acc. was cultivated on a large
scale. Mollisin (1;= 8-(dichloroacetyl)-5-hydroxy-2, 7-dimethylnaphthalene-1, 4-dione) and …
scale. Mollisin (1;= 8-(dichloroacetyl)-5-hydroxy-2, 7-dimethylnaphthalene-1, 4-dione) and …